Lupin Limited has informed the Exchange regarding a press release dated May 26, 2025, titled "Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at theAmerican Society of Clinical Oncology - Annual Meeting 2025".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has announced that Phase 1 clinical data for its experimental cancer drug LNP7457, a PRMT5 inhibitor, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. PRMT5 inhibitors are a class of targeted cancer therapies being studied for tumors that depend on this enzyme. Phase 1 trials are the earliest stage of human testing and primarily assess safety, dosage, and early signals of effectiveness in a small group of patients. Presentation at ASCO, one of the world's most prestigious oncology conferences, means the data will be reviewed by global cancer researchers and oncologists. This is a pipeline and research update, not a commercial milestone, as the drug is still years away from potential approval even if results are positive.
No immediate impact on revenue or earnings since the drug is in very early-stage trials. Positive data could support long-term pipeline value, but investors should treat this as an R&D progress update rather than a near-term stock catalyst.